In the wake of her sister's tragic passing, acclaimed Australian actress Paula Duncan is spearheading a powerful campaign to raise funds for life-saving research into gynaecological cancers. The loss of Carmen Duncan to vaginal cancer in 2019 at the age of 76 has left a profound impact on Paula, who is now using her grief as a catalyst for change. What makes this story particularly compelling is the stark contrast between the advancements in medical science and the grim reality of gynaecological cancer outcomes. Despite the progress made in treating other forms of cancer, the survival rates for many gynaecological cancers have remained largely unchanged for decades, a fact that is both alarming and deeply concerning.
In my opinion, the underfunding of gynaecological cancer research is a critical issue that demands attention. Across Australia, 19 people are diagnosed with a gynaecological cancer every day, yet these cancers remain among the most underfunded areas of cancer research. This is despite the fact that they have received the lowest aggregate investment over the past 20 years, contributing to survival rates that lag significantly behind other cancers. One thing that immediately stands out is the stark disparity between the advancements in medical science and the outcomes for gynaecological cancers. While other forms of cancer have seen significant improvements in survival rates, gynaecological cancers have remained largely unchanged, with some types, like vaginal cancer, having a five-year survival rate of just 53.6 per cent.
What many people don't realize is that gynaecological cancers are not just a woman's issue; they affect men as well. Vaginal cancer, for instance, is a rare and aggressive disease that has taken the life of Carmen Duncan. This raises a deeper question: why are these cancers still so poorly understood and underfunded, despite the personal and societal impact they have? In my view, the answer lies in the lack of public awareness and understanding of these cancers. Many people are unaware of the risks and symptoms, which can lead to delayed diagnosis and treatment. This, in turn, contributes to the low survival rates and the need for more research and funding.
To address this issue, Paula Duncan is spearheading efforts to change the trajectory through the upcoming Venus Mother's Day Lunch. This event combines expert insight, lived experiences, and community action to raise critical funds for research across all gynaecological cancers, including ovarian, uterine (endometrial), cervical, vaginal, and vulvar cancers. The event will feature a panel discussion, 'Cause and Effect of Vaginal and Vulval Cancer,' with leading experts and advocates, including Professor Alison Brand AM, Director of Australia New Zealand Gynaecological Oncology Group (ANZGOG) and Director of Gynaecological Oncology at Westmead Hospital, and survivor advocate Jane Hancox. The lunch will be hosted by beloved Australian performer Jean Kittson, with special guest performances.
From my perspective, the Venus Mother's Day Lunch is a significant step forward in the fight against gynaecological cancers. It brings together experts, advocates, and the community to raise awareness, funds, and support for research. The event is a powerful example of how personal tragedy can be transformed into a force for good, driving meaningful change and improving outcomes for future generations. The funds raised will support critical gynaecological cancer research and initiatives aligned with the Gynaecological Cancer Transformation Initiative (GCTI), which is working to address decades of systemic underinvestment and deliver better outcomes for future generations.
In conclusion, the campaign led by Paula Duncan is a testament to the power of personal tragedy to inspire action and drive change. It is a call to action for the global community to come together and address the underfunding of gynaecological cancer research. By supporting this campaign, we can ensure that no one has to endure what Carmen Duncan went through, and that future generations will have access to the best possible care and treatment for these devastating cancers.
